Literature DB >> 16711307

Primary care house staff attitudes toward osteoporosis management.

Terry A McNearney1, Angela J Shepherd, Ajoy Chhabra, Niti Goel.   

Abstract

OBJECTIVE: This study assessed possible institutional and patient-related factors influencing the delivery of postmenopausal osteoporosis (PMO) care and the diagnostic priority placed on addressing PMO, relative to other common medical conditions, by primary care house staff at our institution.
METHODS: A questionnaire was designed and distributed to eligible house staff at our institution.
RESULTS: Approximately 50% (n = 52) of the house staff participated. The supervising clinic attending, patients' lack of insurance, accessibility to medical care, comorbid conditions, and university formulary were reported to influence decisions regarding osteoporosis care. Osteoporosis was ranked 6th of 7 medical issues (hypertension, coronary artery disease, diabetes, hypercholesterolemia, adult immunizations, osteoporosis, thyroid disease) to address during a comprehensive medical visit.
CONCLUSIONS: Our institution's primary care house staff reported multiple influences on decision making regarding osteoporosis care, and an overall low priority to address this issue. Based on PMO's associated morbidity and mortality, primary care training programs are challenged to put resources toward optimizing house staff delivery of osteoporosis care.

Entities:  

Mesh:

Year:  2006        PMID: 16711307     DOI: 10.1097/01.smj.0000216495.79818.eb

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

1.  Appraising osteoporosis care gaps.

Authors:  Thomas P Olenginski; Jana L Antohe; Elaine Sunderlin; Thomas M Harrington
Journal:  Rheumatol Int       Date:  2011-11-20       Impact factor: 2.631

2.  Successful direct intervention for osteoporosis in patients with minimal trauma fractures.

Authors:  I Kuo; C Ong; L Simmons; D Bliuc; J Eisman; J Center
Journal:  Osteoporos Int       Date:  2007-06-30       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.